First experiences with detecting ALK (anaplastic lymphoma kinase) gene rearrangement and administration of crizotinib in selected patients with non-small cell lung cancer (NSCLC)

Abstract

Authors present first experience in Czech Republic on diagnostic of EML-4 ALK rearrangements in non-small cell lung cancer patients and two case reports of NSCLC patients with tumour EML-4 ALK rearrangements, successfuly treated by crizotinib are also presented.

Keywords

• EGFR mutation
• KRAS mutation
• ALK gene translocation
• molecularly targeted therapy
• crizotinib